- Advertising
- Asia
- Bangladesh
- Biological Inventions
- BRAND VALUATION
- China
- Comparative Advertisement
- Copyright
- Copyright Infringement
- Copyright Litigation
- Counterfeiting
- Covid
- Data Protection
- Design
- Digital Marketing Rights
- DRM
- Electronics
- Geographical Indication
- India
- Indian Patents Act
- Indonesia
- Intellectual Property
- Interim Injunction
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- Japan
- Legal Issues
- Licensing
- Malaysia
- Myanmar
- NCLT
- NEPAL
- Net Neutrality
- News & Updates
- Office
- Patent Commercialisation
- Patent Cooperation Treaty
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Opposition
- Patent Prosecution
- Patent Rule Amendment
- Patent Term Extension
- Patents
- pharma
- Philippines
- Punitive Damages
- Section 3(D)
- section 64
- Singapore
- South-east Asia
- Technology
- Technology Transfer
- Thailand
- Trademark
- Trademark Litigation
- UAE
- Uncategorized
- USPTO
- Vietnam
- WIPO
Counterfeiting Medicines in India: why is there a need for IPR?
Counterfeit Medicines India and piracy is a massive global problem that affects practically every industry sector on the planet. India is no different, with widespread counterfeiting, piracy, and smuggling having serious economic, health, and safety ramifications in the country. Small businesses buy counterfeit technology or equipment, either deliberately or inadvertently, and incur unplanned costs in … Continue reading Counterfeiting Medicines in India: why is there a need for IPR?
Read more »3D Printing In Pharmaceutical Industry
3D Printing In Pharmaceutical Industry: The technology and formulation developed to efficiently transport a pharmacologically active molecule in the body in order to achieve therapeutic efficacy in a safe manner is referred to as drug delivery. Controlling the release profile, which changes the pharmacokinetics of a medicine, can increase the efficiency and safety of a … Continue reading 3D Printing In Pharmaceutical Industry
Read more »The Delhi High Court has ordered the controller general of patents designs and trade marks | Extension Of Time For Filing Opposition Of Trademark Advertised During Pandemic (Covid-19): Directions Of Delhi High Court To Trademark Registry
During the period of the Covid-19 pandemic many oppositions were filed beyond the four months period of limitation and the same have also been entertained by the Controller General of Patents, Designs, and Trade Marks (CGPDTM). The Delhi High Court has ordered the Controller General of Patents, Designs, and Trade Marks (CGPDTM) to allow more … Continue reading The Delhi High Court has ordered the controller general of patents designs and trade marks | Extension Of Time For Filing Opposition Of Trademark Advertised During Pandemic (Covid-19): Directions Of Delhi High Court To Trademark Registry
Read more »Colour As A Trade Dress In The Pharmaceutical Industry
Introduction The notion of trade dress is defined in Section 2(zb) of the Trademarks Act 1999, which defines a ‘trademark’ in broad terms, including shape, packaging, and color combinations, as long as they can be graphically depicted and identify goods or services. Colors and color combinations are important in distinguishing products on the market. A … Continue reading Colour As A Trade Dress In The Pharmaceutical Industry
Read more »Commentary On Compulsory Licensing Under The Patents Act, 1970
Patents provide exclusive rights to the patent proprietors over their novel creations. There is an implied expectation that the owners of the patents will work the patented inventions pragmatically on a commercial scale without any undue delay. However, in certain cases, these rights are exploited for anti-competitive practices. In order to prevent such abuse, the … Continue reading Commentary On Compulsory Licensing Under The Patents Act, 1970
Read more »Sofosbuvir: The Next Pre-Grant Opposition Target by I-MAK
After anti-influenza drug Tamiflu (Oseltamivir Phosphate) and antiretroviral drug Viread, Gilead Sciences is again back in news, this time with its hepatitis C (HCV) drug Sofosbuvir. Like Tamiflu and Viread’s pre-grant opposition, Sofosbuvir patent application is also facing pre-grant opposition. Non-profit group I-MAK (Initiative for medicines access and knowledge) has filed a pre-grant opposition against … Continue reading Sofosbuvir: The Next Pre-Grant Opposition Target by I-MAK
Read more »Sun Pharmaceuticals v. Eli Lilly: Doctrine of Obviousness-Type Double Patenting
December 16, 2010 - 8:38 am
Categories:
Patent Litigation
Pharma/Biotech Patent Litigations
0 Comments
A remarkable latest change in the Patentability has risen from the decision of the Federal Circuit in the case Sun Pharmaceuticals v. Eli Lilly, over the later’s patent that claimed the use of gemcitabine (GEMZAR), a drug to treat cancer. Sun Pharma moved to lower court to invalidate this patent on the grounds of obviousness-type … Continue reading Sun Pharmaceuticals v. Eli Lilly: Doctrine of Obviousness-Type Double Patenting
Read more »